Fermenta Biotech Ltd
Fermenta Biotech Ltd Q1 FY25 Results & Presentation Highlights: Revenue, Margins & Order Book
Q1 FY25 investor presentation: what the company reported on revenue, margins and projects.
Based on Fermenta Biotech Ltd's Q1 FY25 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the presentation reports, not management guidance.
The short version
The presentation does not explicitly provide quarterly revenue, sales, or volume figures. The presentation reports the following Annual (FY24) standalone financial figures (no quarterly EBITDA/PAT explicitly reported): - Operational EBITDA: INR 370 Mn, down 3.6% YoY from INR 384 Mn in FY23. - Operational EBITDA Margin: 12.05%, up 37 bps from 11.68% in FY23. - Profit After Tax (PAT): Loss of INR 187 Mn, improved 67.2% YoY from loss of INR 570 Mn in FY23. - No explicit quarterly EBITDA, operating margin, or PAT figures are provided. - The presentation does not state any explicit margin outlook or target for future quarters or years.
From Fermenta Biotech Ltd's Q1 FY25 earnings-call transcript · updated 24 Sept 2026.
Revenue & Sales Performance
- The presentation does not explicitly provide quarterly revenue, sales, or volume figures.
- The Annual Standalone Financial Performance (Page 26) reports full-year FY24 operational revenue of INR 3,071 million, down 6.6% YoY from INR 3,289 million in FY23.
- Operational EBITDA for FY24 was INR 370 million, a slight dip of 3.6% YoY.
- No explicit quarterly volume or revenue outlook is stated in the presentation.
- The company’s strategic focus is on nutrition business growth and exiting non-core areas (Page 21).
- Growth drivers emphasize expanding Vitamin D3 and nutraceutical products and increasing manufacturing capacities but without explicit numeric revenue or volume guidance for upcoming quarters.
2 more points management made on revenue & sales performance
Profitability & Margins
See what Fermenta Biotech Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- A new plant is being set up at Kullu, Himachal Pradesh, for customized premixes (Page 20).
- The company has commercialized Fortified Rice Kernel (FRK) from its newly commissioned manufacturing facility in Andhra Pradesh (Page 18).
- New product launch timelines related to capacity expansion or projects include:
- Vitamin K1 launched in Q1 FY24
- Vitamin E50 and Fortified Rice Kernel in Q2 FY23
- Customized premix in Q1 FY24
- Plant Based Vitamin D3 and Vitamin D3 Spray Dried 100 targeted for Q2 FY25 (Page 19).
2 more points management made on capital expenditure plans
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Fermenta Biotech Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
Fermenta Biotech Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹122 Cr, net profit ₹19 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Fermenta Biotech Ltd's management said in earlier quarters
- Q4 FY24 earnings call analysis →
- Q1 FY25 earnings call analysis →
- Q4 FY25 earnings call analysis →
- Q2 FY25 earnings call analysis →
- Q4 FY22 earnings call →
- Q3 FY22 earnings call →
- Q2 FY22 earnings call →
- Q1 FY22 earnings call →
- Q1 FY22 earnings call →
- Q3 FY21 earnings call →
- Q2 FY21 earnings call →
- Q2 FY21 earnings call →
Others in Pharmaceuticals & Biotechnology this season
- NGL Fine Chem Ltd (Q1 FY25)
Q1 FY25 revenue from operations: ₹90.75 crores, up 27.75% year-on-year (YoY) from ₹71.04 crores in Q1 FY24 (Page 8). Key investor presentation takeaways from NG
- Shree Ganesh Remedies Ltd (Q1 FY25)
Q1FY25 Revenue from Operations: ₹24.78 crore, down 8% YoY from Q1FY24's ₹26.84 crore. Key investor presentation takeaways from Shree Ganesh Remedies Ltd's Q1 FY
- Themis Medicare Ltd (Q1 FY25)
122.99 Cr, up 27.26% YoY from Rs. Key investor presentation takeaways from Themis Medicare Ltd's Q1 FY25 investor presentation — and how it ranks against sector
Frequently Asked Questions
What were Fermenta Biotech Ltd Q1 FY25 results?
The presentation does not explicitly provide quarterly revenue, sales, or volume figures. The presentation reports the following Annual (FY24) standalone financial figures (no quarterly EBITDA/PAT explicitly reported): - Operational EBITDA: INR 370 Mn, down 3.6% YoY from INR 384 Mn in FY23. - Operational EBITDA Margin: 12.05%, up 37 bps from 11.68% in FY23. - Profit After Tax (PAT): Loss of INR 187 Mn, improved 67.2% YoY from loss of INR 570 Mn in FY23. - No explicit quarterly EBITDA, operating margin, or PAT figures are provided. - The presentation does not state any explicit margin outlook or target for future quarters or years.
What is Fermenta Biotech Ltd share price analysis?
Fermenta Biotech Ltd currently shows a neutral. The stock trades at a P/E of 25.5 with a market cap of ₹1,395 Cr. Investors should review the full earnings analysis for detailed insights.
Is Fermenta Biotech Ltd planning capital expenditure?
A new plant is being set up at Kullu, Himachal Pradesh, for customized premixes (Page 20).
Keep Fermenta Biotech Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.